Tubulis创建的目标是通过在ADCs开发的所有方面进行创新，解决该领域的主要瓶颈，以最大化ADCs的整体性能。该公司的平台允许使用传统有效载荷之外的载荷类别，并通过新型化学基团，扩展抗体和载荷之间的偶联选择，从而实现稳定的高药物-抗体比(DAR)。According to the agreement terms, Tubulis will receive a prepayment of $20 million; if Gilead exercises the option, an additional $30 million option fee must be paid. In addition, Tubulis may also receive up to $0.415 billion for development and commercialization milestone payments.
Zhixun Finance and Economics APP learned that Gilead Sciences (Gilead Sciences) (GILD.US) and Tubulis announced today that the two parties have signed an exclusive option and license agreement aimed at jointly discovering and developing antibody-drug conjugates (ADCs) targeting solid tumor targets. Under the agreement, Gilead will gain access to Tubulis' proprietary technology platforms Tubutecan and Alco5. Both parties will collaborate to select the most suitable technical solution.
Tubulis will lead the discovery and development work of the lead candidate drug, designing an ADC candidate drug based on topoisomerase I inhibitors. The drug will have excellent biophysical properties and stability, aiming to address current treatment challenges such as inadequate durability of efficacy and off-target toxicity issues.
Tubulis' goal is to innovate in all aspects of ADC development to solve the major bottlenecks in the field and maximize the overall performance of ADCs. The company's platform allows for payload categories beyond traditional payloads and expands coupling choices between antibodies and payloads through novel chemical groups to achieve stable high drug-antibody ratios (DAR).
In March of this year, the company completed a Series B financing of nearly $0.14 billion, with the funds mainly used to support the clinical development of Tubulis' next-generation ADCs, and to help achieve clinical concept validation of the flagship candidate drugs TUB-040 and TUB-030. TUB-040 targets the tumor antigen Napi2b, a target well characterized in ovarian and lung cancer. TUB-030 targets 5T4, an antigen frequently overexpressed in solid tumors. The preclinical concept validation data of these two candidate drugs was reported at this year's American Association for Cancer Research (AACR) Annual Meeting in April.
According to the agreement terms, Tubulis will receive a prepayment of $20 million; if Gilead exercises the option, an additional $30 million option fee must be paid. In addition, Tubulis may also receive up to $0.415 billion for development and commercialization milestone payments. Tubulis will be responsible for the early research and development work of the ADC project. If Gilead chooses to exercise the exclusive license, it will be responsible for the subsequent development and commercialization of all products generated by the collaboration.
